328 related articles for article (PubMed ID: 26449391)
1. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
[TBL] [Abstract][Full Text] [Related]
2. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
4. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
8. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
9. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
11. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
Kitayama H; Tsuji Y; Sugiyama J; Doi A; Kondo T; Hirayama M
Int J Clin Oncol; 2015 Dec; 20(6):1051-6. PubMed ID: 25822106
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A; Okamoto I; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
J Clin Oncol; 2022 Jan; 40(2):180-188. PubMed ID: 34793245
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
18. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Hesketh PJ; Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
[TBL] [Abstract][Full Text] [Related]
19. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
